Skip to main
ANNX

Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon, Inc (ANNX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Annexon is a biopharmaceutical company focused on developing C1q inhibitors for autoimmune and neurodegenerative diseases. Lead drug vonaprument has shown promising results in clinical trials for geographic atrophy and Guillain-Barré syndrome, but faces risks and potential competition. With FDA/EMA submissions accepted for another drug and a CFO with relevant experience, the company has potential for success in this market. Additionally, vonaprument has potential advantages over other treatments and a large market expected to generate significant revenue.

Bears say

Annexon is facing a number of challenges in its development and commercialization plans. The company's stock has a negative outlook, driven by concerns about the success of their lead drug vonaprument and potential competition from other approved drugs. While the company's Chief Innovation Officer, Dr. Ted Yednock, plays a key role in their complement platform, there are concerns about their ability to replicate success in larger trials and effectively market their products against larger competitors.

Annexon, Inc (ANNX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annexon, Inc (ANNX) Forecast

Analysts have given Annexon, Inc (ANNX) a Buy based on their latest research and market trends.

According to 6 analysts, Annexon, Inc (ANNX) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annexon, Inc (ANNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.